Celcuity strengthens case for ASCO-spotlighted breast cancer drug
BioPharma Dive
The new data could support a broader approval submission for a therapy that is already under review and set to be showcased at the year s biggest meeting for cancer research.
pharminent
May 4, 2026 (Last updated: May 5, 2026)
BioPharma Dive
The new data could support a broader approval submission for a therapy that is already under review and set to be showcased at the year s biggest meeting for cancer research.
